News Snapshot:
LOS ANGELES, May 17 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Tuesday granted emergency use authorization for a booster dose of the Pfizer-BioNTech COVID-19 vaccine for children 5 through 11 years of age at least five months after completion of the primary vaccine series. On Jan. 3, the FDA authorized the use of a single booster dose of the Pfizer-BioNTech COVID-19 vaccine for individuals 12 through 15 years of age after completion of primary vaccination. The FDA's decision on Tuesday means anyone ages 5 and older is now eligible for at least one booster dose. "While it...